Medtronic MDT After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI

Other financials

Revenue$9.8B+9.9%

Gross profit$6.4B+10.9%

Operating income$1.9B+30.4%

Net income$1.2B+17.8%

EPS (diluted)$0.97+18.3%

Cash & equivalents$1.9B-12.1%

Total debt$29.2B-1.6%

Total equity$49.5B+3.0%

Total assets$93.0B+1.5%

Operating cash flow$2.6B+1.8%

CapEx$488.0M+6.3%

Free cash flow$2.1B+0.8%

Market cap$101.86B-3.8%

Enterprise value$129.12B-3.2%

P/E21.2×-1.5×

P/S2.8×-0.4×

Gross margin65%-0.3pp

Operating margin17.8%0.0pp

Net margin13.2%-0.7pp

Return on equity9.8%+0.4pp

Debt / equity0.6×0.0×

Current ratio2.1×+0.3×

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept mdt:UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Medtronic's after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI?: Medtronic (MDT) reported after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI of -$116M in Q4 2025.
What is the long-term trend for Medtronic's after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI?: Over 2 years (2021 to 2025), Medtronic's after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI has grown at a -23.3% compound annual growth rate (CAGR), from -$253M to -$149M.